title: Clinical response to crizotinib retreatment after acquisition of drug resistance.
authors.affiliation: Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Matsuoka
authors.forename: Takayasu
authors.initials: T
authors.lastname: Kurata
authors.forename: Isamu
authors.initials: I
authors.lastname: Okamoto
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Kaneda
authors.forename: Kaoru
authors.initials: K
authors.lastname: Tanaka
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nakagawa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics; D002945:Cisplatin / Q000008:administration & dosage; D000077547:Crizotinib; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics; D015321:Gene Rearrangement; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008297:Male; D008869:Microtubule-Associated Proteins / Q000235:genetics; D058990:Molecular Targeted Therapy / Q000379:methods*; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D000068437:Pemetrexed; D011720:Pyrazoles / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D019233:Retreatment; D012697:Serine Endopeptidases / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D018797:Cell Cycle Proteins; C522504:EML4-ALK fusion protein, human; D005971:Glutamates; D008869:Microtubule-Associated Proteins; D015514:Oncogene Proteins, Fusion; D011720:Pyrazoles; D011725:Pyridines; D000068437:Pemetrexed; D000077547:Crizotinib; D006147:Guanine; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; C415585:EML4 protein, human; D012697:Serine Endopeptidases; D002945:Cisplatin